Identification of autoantibody to melanocytes and characterization of vitiligo antigen in vitiligo patients

Journal of Dermatological Science

Volumn 11, Issue 2, 1996, Pages 111-120

  Park, Yoon Kee ^a   Kim, Nam Soo ^a   Hann, Seung Kyung ^a   Im, Sungbin ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Autoantibody; Vitiligo; Vitiligo antigen

Indexed keywords

AUTOANTIBODY; STEROID;

ARTICLE; AUTOIMMUNITY; BEHCET DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOCYTE; PRIORITY JOURNAL; VITILIGO;

EID: 0030019651     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/0923-1811(95)00427-0     Document Type: Article

References (28)

1. Lerner AB: On the etiology of vitiligo and gray hair. Am J Med 51: 141-147, 1971.
2. Hann SK, Song MS, Park YK, Ahn SK: Childhood vitiligo. Ann Dermatol 3: 112-118, 1991.
3. Howantz N, Nordlund JJ, Lerner AB, Bystryn JC: Antibodies to melanocytes: Occurrence in patients with vitiligo and chronic mucocutaneous candidiasis. Arch Dermatol 117: 705-708, 1981.
4. Naughton GK, Eisinger M, Bystryn JC: Antibodies to normal human melanocytes in vitiligo. J Exp Med 158: 246-251, 1983.
5. Morris DA, Kissinger RM, Naughton GK, Bystryn JC: Evidence for immunologic mechanisms in human vitiligo: Patient's sera induce damage to human melanocytes in vitro by complement mediated damage and antibody dependent cellular cytotoxicity. J Invest Dermatol 90: 783-789, 1988.
6. SK Hann, YK Park, KY Chung, HI Kim, S Im, JH Won: Peripheral blood lymphocyte imbalance in Korean with active vitiligo. Int J Dermatol 32: 286-289, 1993.
7. Betterle C, Mirakian R, Doniach G, Bottazo F: Antibodies to melanocytes in vitiligo. Lancet 1: 159, 1984.
8. Hertz KC, Gazze LA, Kirkpatrick CH, Karz SI: Autoimmune vitiligo: Detection of antibodies to melanin-producing cells. N Engl J Med 297: 634-637, 1977.
9. Bystryn JC, Naughton GK: The significance of vitiligo antibodies. J Dermatol 12: 1-9, 1985.
10. Harning R, Cui J, Bystryn JC: Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 97: 1078-1080, 1991.
11. Cunliffe WJ, Hall R, Newell DJ: Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 80: 135-139, 1968.
12. Dawber RPR: Vitiligo in mature onset diabetes mellitus. Br J Dermatol 80: 275-278, 1968.
13. Hovitz J, Schwartz M: Vitiligo, achlorhydria and pernicious anemia. Lancet 1: 1331-1334, 1971.
14. McGregor BC, Karz HI, Doe RP: Vitiligo and multiple glandular insufficiencies. J Am Med Assoc 219: 724-725, 1972.
15. Hann SK, Park YK, Kim HS, Lee YJ, Im S: Increased incidence of anti-smooth muscle antibody in Korean vitiligo patients. J Dermatol (Tokyo) 20: 679-683, 1993.
16. Naughton GK, Reggiordo D, Bystryn JC: Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 15: 978-981, 1986.
17. Cui J, Arita Y, Bystryn JC: Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 100: 812-815, 1993.
18. Cui J, Harning R, Henn M, Bystryn JC: Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 98: 162-165, 1992.
19. Eisinger M, Marko O: Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc Natl Acad Sci USA 79: 2018-2022, 1982.
20. Im S, Hann SK, Park YK, Kim HI: Culture of melanocytes obtained from normal and vitiligo subjects. Yonsei Med J 33: 344-350, 1992.
21. Bentley DM, Guckian VA, Stinnett JD, Morris RE: Failure to demonstrate a role for line Ib tumor-associated surface antigen in the etiology of age-dependent polioencephalomyelitis. Mol Immunol 19: 983-989, 1982.
22. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-689, 1970.
23. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheet: procedures and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
24. Moellmann GE, Krass P, Halaban R, Kuklinska E, Lerner AB: On the subject of serum antibodies to melanocytes in vitiligo. J Invest Dermatol 84: 333A, 1985.
25. Hann SK, Kim HI, Im S, Park YK, Cui J, Bystryn JC: The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients. J Dermatol Sci 6: 201-205, 1993.
26. Cui J, Harning R, Henn M, Bystryn JC: Antigen expression and antibody function in vitiligo. Presented at the International Pigment Cell Conference, Japan, CS-D9, p. 95, 1990.
27. Cui J, Arita Y, Eisinger M, Bystryn JC: Characterization of vitiligo antigens. J Invest Dermatol 98: 600, 1992.
28. Xia P, Geoghegan WK, Duvic M, Jordan RE: Western blot analysis of vitiligo and alopecia areata autoantibody reactivity with cultured normal human melanocytes. J Invest Dermatol 98: 630, 1992.